ATP-gated P2X7 receptor as a potential target for prostate cancer

Hum Cell. 2022 Sep;35(5):1346-1354. doi: 10.1007/s13577-022-00729-x. Epub 2022 Jun 3.

Abstract

Prostate cancer is the most common malignancy of the male genitourinary system and is one of the leading causes of male cancer death. The P2X7 receptor is an important member of purine receptor family. It is a gated ion channel with adenosine triphosphate (ATP) as the ligand, which exists in a variety of immune tissues and cells and can be involved in tumorigenesis and tumor progression. Studies have shown that the P2X7 receptor is abnormally expressed in prostate cancer, and is related to the level of prostate-specific antigen, P2X7 receptor may be an early biomarker of prostate cancer. The P2X7 receptor is essential in the occurrence and development of prostate cancer. The P2X7 receptor mainly affects the invasion and metastasis of prostate cancer cells through epithelial mesenchymal transition/invasion-related genes and the PI3K/AKT and ERK1/2 signaling pathways. The P2X7 receptor could be a promising therapeutic target for prostate cancer.

Keywords: ATP; Invasion; Metastasis; P2X7 receptor; Prostate cancer.

Publication types

  • Review

MeSH terms

  • Adenosine Triphosphate* / metabolism
  • Humans
  • Male
  • Phosphatidylinositol 3-Kinases / metabolism
  • Prostatic Neoplasms* / pathology
  • Receptors, Purinergic P2X7* / genetics
  • Receptors, Purinergic P2X7* / metabolism
  • Signal Transduction / genetics

Substances

  • P2RX7 protein, human
  • Receptors, Purinergic P2X7
  • Adenosine Triphosphate